Press Enter to search · Esc to close
A new gene-metabolite map suggests incretin-pathway drugs act on a web of cardiovascular and metabolic systems — not just glucose. Here's what that means for patients in 2026.
A new federal survey puts a real number on how many Americans with diabetes are now on GLP-1 shots — and it's reshaping what we should expect from the next wave of metabolic drugs.
A new PRISMA-guided meta-analysis pools data from 179 cohorts to quantify the years diabetes can cost — and what that means for the metabolic choices we make in the meantime.
Two new studies reframe the conversation around metabolic health in later life — pointing to skeletal muscle, mitochondria, and medication choice as the quiet variables that matter.
A 95-patient multi-site study suggests advanced hybrid closed-loop pumps — long the domain of type 1 diabetes — can safely tighten glucose control in insulin-using adults with type 2. The results are encouraging, and worth reading carefully.